As the COVID-19 pandemic dragged on into its second year in 2021, the diabetes community eagerly awaited the rollout of several new devices—insulin pumps, smart insulin pens, and more—only to see the development or approval of many products take longer than expected. Still, a few new devices made it to the market, and even more are expected to launch in 2022.
At the same time, 2021 saw a number of existing diabetes drugs get approved to treat related conditions like chronic kidney disease and obesity—even for people without diabetes. And lower-cost insulin options continued to expand, hinting at the possibility of even more